Cellosaurus cell line YUSIT1-B11 (CVCL

Cross-references
Cell line name	YUSIT1-B11
Accession	CVCL_R736
Resource Identification Initiative	To cite this cell line use: YUSIT1-B11 (RRID:CVCL_R736)
Comments	Selected for resistance to: ChEBI; CHEBI_75045; Dabrafenib (Tafinlar; GSK2118436). Derived from site: Metastatic; Not specified.
Sequence variations	Mutation; HGNC; HGNC:1097; BRAF; Simple; p.Val600Lys (c.1798_1799delGTinsAA); ClinVar=VCV000375941; Zygosity=Heterozygous (from parent cell line).
Disease	Melanoma (NCIt: C3224)
Species of origin	Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy	Parent: CVCL_A747 (YUSIT1)
Sex of cell	Male
Age at sampling	67Y
Category	Cancer cell line
Publications	PubMed=22389471; DOI=10.1158/1535-7163.MCT-11-0989 James G. Greger, Stephen D. Eastman, Vivian Zhang, Maureen R. Bleam, Ashley M. Hughes, Kimberly N. Smitheman, Scott H. Dickerson, Sylvie G. Laquerre, Li Liu, Tona Morgan Gilmer; Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations. Mol. Cancer Ther. 11:909-920(2012) Patent=US20130231347 Maureen R. Bleam, Tona Morgan Gilmer, James G. Greger, Sylvie G. Laquerre, Li Liu; Method of treatment with BRAF inhibitor. Patent number US20130231347, 05-Sep-2013
Cell line databases/resources	cancercelllines; CVCL_R736
Encyclopedic resources	Wikidata; Q54995803
Polymorphism and mutation databases	Cosmic; 1921231
Entry history
Entry creation	05-Nov-2013
Last entry update	19-Dec-2024
Version number	15